Exxon Mobil Corporation (XOM)
Verdict history · XOM
Every call Verdix has made on XOM.
While a verdict holds, its return keeps accumulating from the day the call was made — it resets only when the verdict itself changes.
Click any date below to read that write-up
The prior WAIT call at $160.10 reflected a panel that saw no reason to buy ahead of clarity. The shift to BALANCED at $165.11 reflects a panel that now sees enough confirming data (rising FY2026 EPS estimates, management's specific FCF-doubling commitment, and a clean Stage 2 uptrend) to keep existing positions, even though five of six voices still object to adding at today's price. The lone buyer upgrade from The GARP Operator is not enough to tip the call given the consensus target sits only 3% above the current quote.
See methodology for how verdicts are produced. Full track record →
The panel’s split verdict on XOM — and where they disagree.
The case for and against roughly balance — no clear edge at today's price.
NYSE · Energy · 2026-08-22 · analysis, not advice
Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.
Verdict
BalancedMEDIUM confidence
Why
ExxonMobil earns a BALANCED from a split panel: every voice agrees the business is well-run and the Guyana-driven FCF doubling story is credible, but five of six argue the 56% rally off the 52-week low has already priced in the inflection, leaving only single-digit upside to consensus targets. The debate turns on whether a 13.7× forward multiple fairly compensates for commodity-cycle risk, with a breakout above the $176 all-time high or a pullback toward $150 as the two paths that would resolve the standoff.Level to watch
Key resistance 169.68+2.8% from 165.11
Next catalyst
Trigger to confirm the breakout: A weekly close above $176.41 on expanding volume (1.5× average or higher) would convert the price-objecting neutrals and shift the call to BUY.The panel's take
Verdict: BALANCED · Conviction: MEDIUM · Last price: 165.11 · Changed from WAIT
Panel: 1 Bullish · 5 Neutral · 0 Bearish → BALANCED
What changed since 2026-08-15:
- Price: 160.1 → 165.11 (+3.13%)
- Panel: 1 of 6 → 1 of 6 still Bullish, unchanged — same 6 of 6 split
- Trigger: A weekly close above the $176.41 all-time high on expanding volume would confirm the breakout and convert the price-objecting neutrals — The Macro Opportunist explicitly names that trigger, and The GARP Operator would add — shifting the call to BUY.
- Verdict: WAIT → BALANCED
The prior WAIT call at $160.10 reflected a panel that saw no reason to buy ahead of clarity. The shift to BALANCED at $165.11 reflects a panel that now sees enough confirming data (rising FY2026 EPS estimates, management's specific FCF-doubling commitment, and a clean Stage 2 uptrend) to keep existing positions, even though five of six voices still object to adding at today's price. The lone buyer upgrade from The GARP Operator is not enough to tip the call given the consensus target sits only 3% above the current quote.
The panel is unanimous that XOM is a well-run business with a genuine FCF catalyst — even The Forensic Skeptic, the most skeptical, doesn't call it a short. But five of six voices see the 56% rally off the 52-week low as having already priced in the Guyana inflection, leaving only ~3% upside to the consensus target of $169.68. The GARP Operator calls it a Buy but warns against chasing; the other five all want a pullback before committing fresh capital. With zero bears, there is no case to sell — but with only one buyer at today's price, there is no case to add. That is a Hold.
Key levels
Key levels · XOM
USD · as of 2026-08-22Analyst consensus target 169.68 USD · range 142–200
Key support & resistance and analyst consensus — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.
Key resistance is the $176.41 all-time high, the last structural ceiling and the level the stock has been grinding toward on declining volume. Just below it, the $169.68 analyst consensus target reinforces the zone as a sell-the-news band. Key support begins at $160.35 (23.6% Fibonacci retracement of the weekly swing), but the level that matters most is $149.93 — the weekly EMA20, which The Macro Opportunist and the technical scout both treat as the line that separates a healthy uptrend from a Stage 3 transition. The $143.55 40-week SMA and $140.18 weekly EMA50 form a cluster with the $139.85 monthly 38.2% retracement, marking the zone where the structural trend would be tested. The $130 round-number area is the historical accumulation zone where The Moat Compounder, The Asymmetric Bargainer, and The Forensic Skeptic all said they would step in. The analyst consensus target of $169.68 sits just 2.8% above the current price, consistent with the panel's view that upside is limited until the stock proves it can clear the all-time high.
What legendary investors think
We ran Exxon Mobil Corporation past a panel of 6 legendary investors' frameworks.
The panel · 6 investors
The Moat CompounderValue/Quality/Moat⚫ NeutralLow
Signal: The business carries a genuine cost advantage in low-breakeven Guyana and Permian assets, but ROE at 12.58% remains below the 15% threshold this framework requires and the commodity nature of earnings means that return is volatile, not durable. Conviction: Conviction is held in check by the absence of any margin of safety at current prices. A pullback to $125–$130 would be needed to provide the 25%+ cushion this framework demands for a cyclical commodity business.
The Intrinsic-Value ModelerValuation/DCF⚫ NeutralLow
Signal: The base-case DCF points to an equity value of $138–$148 per share, putting the stock above intrinsic value, though the bull case at $170–$195 opens if sustained higher oil prices push margins to 15% and revenue growth to 10% for three years. Conviction: Confidence stays moderate because the terminal value, which dominates any DCF for this business, rests on a 2.5% perpetual growth assumption that the energy transition could easily undercut.
The Asymmetric BargainerContrarian/Deep Value⚫ NeutralLow
Signal: Only one of four Dhandho criteria passes: the business is simple, but downside to the trough at $108 represents a 35% loss, upside to the consensus high of $200 is a modest 21%, and the odds are not overwhelmingly favorable at this stage of the cycle. Conviction: The absence of insider buying, superinvestor accumulation, or genuine market pessimism strips away the asymmetry this framework hunts for, leaving no 'heads I win, tails I don't lose much' setup at the current price.
The GARP OperatorGrowth (GARP)🟢 BullishMed
Signal: A PEG ratio of 1.20 on 14.5% forward EPS growth and a forward P/E of 13.68 signal a quality cyclical trading at a reasonable price, while management's unusually specific commitment to double FCF by 2030 is the kind of concrete forecast this framework treats as a credible signal. Conviction: Conviction is tempered by the 56% rally already in the books: chasing a stock at 52-week highs violates the discipline of buying at a fair price, not a stretched one, and a pullback toward $150 would align the setup with this framework's preference for patience.
The Forensic SkepticContrarian/Forensic⚫ NeutralLow
Signal: The stock trades at 2.6× book value while the average analyst target of $153 sits 7.3% below the current price, a rare bearish gap that historically signals professional skepticism about the valuation, and the GF Value estimate of $125 implies 32% overvaluation by that model. Conviction: The inability to compute tangible book value or a reliable DCF from the available data prevents building a high-conviction thesis in either direction, though every valuation proxy that is calculable points to a negative margin of safety.
The Macro OpportunistMacro/Timing⚫ NeutralMed
Signal: The approach to the $176.41 all-time high on declining volume (0.86× the 50-week average) while the 10-year yield ticks up to 4.7% creates a tired technical setup with a 0.74:1 upside-to-downside ratio, and the marginal buyer is losing conviction at the worst possible spot. Conviction: The macro backdrop of rising rates and tight financial conditions makes this an earnings-momentum trade rather than a macro-driven opportunity, and this framework does not commit serious capital to setups where the macro tailwind is absent.
Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.
Where they agree — and where they clash
Common ground
- All six voices agree XOM is a well-run business with a fortress balance sheet (debt-to-equity 0.16, interest coverage above 50x) and strong cash conversion (operating cash flow at 1.77× net income).
- The Guyana-driven FCF doubling story is considered credible and management's explicit commitment to it is treated as a genuine signal, not empty rhetoric.
- No archetype calls XOM a sell or a short — even the most skeptical voice sees no case to exit an existing position.
- Five of six voices see the 56% rally off the 52-week low as having already priced in much of the Guyana inflection, leaving limited upside to the consensus target near $169.
- The consensus analyst target sits at or below the current price, which every archetype acknowledges as a restraint on near-term return expectations.
The real debate
- The GARP Operator sees a PEG of 1.20 on 14.5% forward growth as reasonable and the Guyana narrative as still misunderstood, while The Forensic Skeptic sees 2.6× book value with no margin of safety for a commodity business and treats the analyst-target gap as a statistically significant bearish signal.
- The Intrinsic-Value Modeler's bull case reaches $195 only if oil sustains above $85 and margins expand to 15%, while The Asymmetric Bargainer stresses that a 35% downside to $108 is what the other side of the same coin looks like if the cycle turns.
- The Macro Opportunist and The Moat Compounder both want a pullback before committing capital, but for different reasons: one reads declining volume into resistance as exhausted momentum, the other demands a 25% margin of safety on principle for any cyclical commodity business.
The question it comes down to: Can XOM deliver the FCF doubling management promises before the commodity cycle turns, and does the current price offer enough reward to compensate for the risk that it will not?
The bottom line
- Trigger to confirm the breakout: A weekly close above $176.41 on expanding volume (1.5× average or higher) would convert the price-objecting neutrals and shift the call to BUY.
- Risk to monitor: A weekly close below the weekly EMA20 at roughly $149.93 would break the intermediate uptrend and signal a Stage 3 transition, invalidating the bullish technical case.
- Next catalyst: Q3 2026 earnings (late October) with consensus at $3.53; a beat that raises FY2027 estimates would directly address the concern that the FCF story is already fully discounted.
- The valuation reset level: A pullback to the $125–$130 zone, aligning with the GF Value estimate and the Moat Compounder's 25% margin-of-safety threshold, would bring the Asymmetric Bargainer and Forensic Skeptic back to the table as potential buyers.
- Further out: A ninth Guyana vessel FID or a sustained Brent crude price above $85/bbl would extend the growth runway and push the Intrinsic-Value Modeler's valuation into the bull case of $170–$195.
contact@verdixhq.com · Published 2026-08-22 · Prices as of 2026-08-22 · Time horizon: 3–12 months · No direct position held in XOM · XOM verdict history → · Methodology →
Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.
Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.
The panel also debated